Key Developments: Carmat SA (ALCAR.PA)

ALCAR.PA on Paris Stock Exchange

29 May 2015
Change (% chg)

€-0.18 (-0.28%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Search Stocks

Latest Key Developments (Source: Significant Developments)

Carmat SA announces appointment of CFO
Tuesday, 26 May 2015 11:45am EDT 

Carmat SA:Appoints Benoît de la Motte as CFO.  Full Article

Carmat announces initial details of analysis of CARMAT Heart implanted in second patient
Tuesday, 5 May 2015 02:30pm EDT 

Carmat SA:Presents first elements of analysis of CARMAT bioprosthesis implanted in second patient.Patient lived virtually normal life with CARMAT prosthesis for nine months.Initial analysis following this relatively long period shows the prosthesis' biocompatibility with organism and blood.Design's fundamentals have thus been corroborated.  Full Article

Carmat Heart implanted in a third patient
Tuesday, 28 Apr 2015 12:00pm EDT 

Carmat SA:Confirms implantation of the CARMAT heart in a third patient at the Georges Pompidou European Hospital.This third implantation of CARMAT heart was carried out on April 8 by Georges Pompidou European Hospital team and went smoothly.  Full Article

Carmat SA to sell up to 50 millions euros worth of shares
Sunday, 25 Jan 2015 07:00pm EST 

Carmat SA:Plans to sell up to 50 million euros ($56 million) of shares in three blocs to help it finance ongoing clinical trials of its artificial heart.Says Bank Kepler Cheuvreux will provide the financing via a so-called contingent equity line, which consists of an immediate first tranche of 20 million euros and a further two optional chunks of 15 million euros each.Says the issue price of the shares will depend on Carmat's prevailing share price, discounted by no more than 6 percent.Says Kepler Cheuvreux will subscribe to a total of 20 million euros of shares in the next 12 months.Says some 303,865 new Carmat SA shares will be issued, or about 6.5 percent of the company's share capital.  Full Article

Carmat to resume first-in-man trial with its bioprosthetic heart
Wednesday, 16 Jul 2014 02:00pm EDT 

Carmat SA:Obtains approval to resume first-in-man trial with its bioprosthetic heart.Patient enrollment put on hold in March to allow data from first implanted prosthesis to be analyzed.Favorable opinion regarding resumption of enrollment of next three patients given by ethics committee, data and safety monitoring board and regulatory authorities.  Full Article

Carmat SA proposes terms of share repurchase program
Sunday, 23 Feb 2014 07:00pm EST 

Carmat SA:Proposes terms of share repurchase program to its Annual General Meeting.Program would authorize it to acquire a maximum of 10 pct of its capital.Maximum price per share 240 euros.Total maximum that could be spent on program 5 million euros.Authorization valid for 18 months.  Full Article

Carmat SA Obtains Approval to Carry Out Human Implants of Its Bioprosthetic Artificial Heart
Monday, 23 Sep 2013 06:30pm EDT 

Carmat SA announced that the Agence Nationale de Securite du Medicament et des produits de sante (ANSM, French health authority) has authorized the Company to carry out the human implants of its bioprosthetic artificial heart on four patients in three approved French hospitals.  Full Article

Carmat SA Subscribes to Contingent Equity Line
Wednesday, 12 Jun 2013 11:46am EDT 

Carmat SA announced that it is taking out a contingent equity line with Kepler Cheuvreux, exercisable by tranches at Carmat SA's discretion, as authorized by the Shareholder Meeting of June 4, 2013. The shares subscribed to by Kepler Cheuvreux can be issued within two years at Carmat SA's request in maximum tranches of 35,000 new shares, or 0.84% of the current share capital. The total number of new shares that could be issued over the coming two years will not exceed 200,000, or 4.81% of the current number of shares. Should the entire contingent equity line be drawn upon, a shareholder who currently owns 1% of the Company’s share capital would see his or her share ownership reduced to 0.95%. For each tranche, the issuance price will depend on the average prevailing share price discounted by no more than 7%. This discount will enable Kepler Cheuvreux, who is a financial intermediary and has no intention of remaining a shareholder in the Company, to underwrite the subscription regardless of market volatility.  Full Article

BRIEF-Carmat appoints Benoit de la Motte as CFO

* Appoints Benoit de la Motte as CFO Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Search Stocks